Haploinsufficiency underlies the neurodevelopmental consequences of SLC6A1/GAT-1 variants
View ORCID ProfileDina Buitrago Silva, Marena Trinidad, Alicia Ljungdahl, Jezrael L. Revalde, Geoffrey Y. Berguig, William Wallace, Cory S. Patrick, Lorenzo Bomba, Michelle Arkin, Shan Dong, Karol Estrada, Keino Hutchinson, Jonathan H. LeBowitz, Avner Schlessinger, Katrine M. Johannesen, Rikke S. Møller, Kathleen M. Giacomini, Steven Froelich, View ORCID ProfileStephan J. Sanders, View ORCID ProfileArthur Wuster
doi: https://doi.org/10.1101/2022.03.09.22271804
Dina Buitrago Silva
1Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, USA
Marena Trinidad
2BioMarin Pharmaceutical Inc., Novato, CA, USA
3Department of Molecular and Cell Biology, University of California, Berkeley, CA, USA
4Innovative Genomics Institute, University of California, Berkeley, CA, USA
Alicia Ljungdahl
5Department of Psychiatry, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA
6Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK
Jezrael L. Revalde
7Department of Pharmaceutical Chemistry, University of California, San Francisco, California, USA
Geoffrey Y. Berguig
2BioMarin Pharmaceutical Inc., Novato, CA, USA
William Wallace
2BioMarin Pharmaceutical Inc., Novato, CA, USA
Cory S. Patrick
5Department of Psychiatry, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA
Lorenzo Bomba
2BioMarin Pharmaceutical Inc., Novato, CA, USA
Michelle Arkin
7Department of Pharmaceutical Chemistry, University of California, San Francisco, California, USA
Shan Dong
5Department of Psychiatry, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA
Karol Estrada
2BioMarin Pharmaceutical Inc., Novato, CA, USA
Keino Hutchinson
8Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
Jonathan H. LeBowitz
2BioMarin Pharmaceutical Inc., Novato, CA, USA
Avner Schlessinger
8Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
Katrine M. Johannesen
9Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
Rikke S. Møller
9Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
10Department of Epilepsy Genetics and Personalized Medicine, Member of ERN Epicare, Danish Epilepsy Centre, Dianalund, Denmark
Kathleen M. Giacomini
1Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, USA
Steven Froelich
2BioMarin Pharmaceutical Inc., Novato, CA, USA
Stephan J. Sanders
5Department of Psychiatry, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA
6Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK
Arthur Wuster
2BioMarin Pharmaceutical Inc., Novato, CA, USA
Article usage
Posted September 26, 2023.
Haploinsufficiency underlies the neurodevelopmental consequences of SLC6A1/GAT-1 variants
Dina Buitrago Silva, Marena Trinidad, Alicia Ljungdahl, Jezrael L. Revalde, Geoffrey Y. Berguig, William Wallace, Cory S. Patrick, Lorenzo Bomba, Michelle Arkin, Shan Dong, Karol Estrada, Keino Hutchinson, Jonathan H. LeBowitz, Avner Schlessinger, Katrine M. Johannesen, Rikke S. Møller, Kathleen M. Giacomini, Steven Froelich, Stephan J. Sanders, Arthur Wuster
medRxiv 2022.03.09.22271804; doi: https://doi.org/10.1101/2022.03.09.22271804
Haploinsufficiency underlies the neurodevelopmental consequences of SLC6A1/GAT-1 variants
Dina Buitrago Silva, Marena Trinidad, Alicia Ljungdahl, Jezrael L. Revalde, Geoffrey Y. Berguig, William Wallace, Cory S. Patrick, Lorenzo Bomba, Michelle Arkin, Shan Dong, Karol Estrada, Keino Hutchinson, Jonathan H. LeBowitz, Avner Schlessinger, Katrine M. Johannesen, Rikke S. Møller, Kathleen M. Giacomini, Steven Froelich, Stephan J. Sanders, Arthur Wuster
medRxiv 2022.03.09.22271804; doi: https://doi.org/10.1101/2022.03.09.22271804
Subject Area
Subject Areas
- Addiction Medicine (386)
- Allergy and Immunology (701)
- Anesthesia (193)
- Cardiovascular Medicine (2859)
- Dermatology (244)
- Emergency Medicine (431)
- Epidemiology (12569)
- Forensic Medicine (10)
- Gastroenterology (807)
- Genetic and Genomic Medicine (4447)
- Geriatric Medicine (402)
- Health Economics (716)
- Health Informatics (2856)
- Health Policy (1050)
- Hematology (376)
- HIV/AIDS (893)
- Medical Education (415)
- Medical Ethics (114)
- Nephrology (464)
- Neurology (4201)
- Nursing (223)
- Nutrition (617)
- Oncology (2205)
- Ophthalmology (626)
- Orthopedics (254)
- Otolaryngology (319)
- Pain Medicine (269)
- Palliative Medicine (83)
- Pathology (488)
- Pediatrics (1172)
- Primary Care Research (483)
- Public and Global Health (6787)
- Radiology and Imaging (1494)
- Respiratory Medicine (902)
- Rheumatology (430)
- Sports Medicine (369)
- Surgery (473)
- Toxicology (57)
- Transplantation (202)
- Urology (174)